EMV Capital: ProAxsis eyes COPD market breakthrough with Imperial College London study

EMV Capital (AIM:EMVC, FRA:NTK1) CEO Dr Ilian Iliev and ProAxsis managing director Dr Louise Ryan Murphy joined Proactive's Stephen Gunnion to discuss the company's commercial transformation and the opportunity emerging from its Imperial College London COPD study. Iliev said EMV Capital has supported ProAxsis since its Queen's University Belfast spin-out, highlighting progress towards operational breakeven and a recent restructuring to broaden US investor access. Ryan Murphy explained that ProAxsis has repositioned as a commercial protease biomarker-led research company, providing kit sales, clinical services and bespoke R&D for pharmaceutical, biotech and research organisations using its patented ProteaseTag technology. The company is collaborating with six global pharmaceutical companies and supported development of Insmed's FDA-approved BRINSUPRI treatment for non-cystic fibrosis bronchiectasis. The near-term priority is the Imperial College COPD study evaluating its NEATstik point-of-use diagnostic test. "The Imperial College London study is a very important milestone study for our expansion plans into the COPD market, which has the potential to increase our revenue by order of magnitude," Ryan Murphy said. A successful outcome could also open the path to a future home self-test and entry into the regulated diagnostics market. For more interviews with listed companies and market insights, visit the Proactive YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications so you never miss future updates. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #ProAxsis #EMVCapital #COPD #Biotech #LifeSciences #RespiratoryHealth #Diagnostics #HealthcareInnovation #ProteaseTag #NEATstik #ClinicalTrials #Pharma #Biomarkers #Investing #ProactiveInvestors